Real-World Studies
Frontline Tagraxofusp in BPDCN: Real-World Outcomes From a 13-Center Retrospective Cohort
Schroeder et alJournal of Hematology & Oncology

A multicenter retrospective study across 13 tertiary centers assessed real-world outcomes of frontline tagraxofusp (TAG), a CD123-directed protein-drug conjugate, in 32 patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) compared to a pre-TAG historical cohort (n = 40). The frontline TAG cohort consisted of an elderly population with a median age of 71.5 years and advanced disease features, including skin (93.8%), bone marrow (84.4%), and peripheral blood (53.1%) involvement.
Frontline TAG induced an overall response rate of 82.1% and a complete response rate of 60.7%. Across a median follow-up of 18.4 months, the 2-year overall survival (OS) was 40.5% and progression-free survival (PFS) was 30.4%. Capillary leak syndrome developed in 53.1% of patients, with grade ≥ 3 manifestations occurring in 47.1%, consistent with the established toxicity profile and showing no novel safety signals.
Nearly half of the cohort successfully transitioned to consolidative allogeneic stem cell transplantation after TAG, which showed a non-significant trend toward improved survival in primary and landmark analyses (HR 0.25, 95% CI 0.06–1.14; p = 0.073). Propensity score-matched analysis between TAG and non-TAG cohorts demonstrated comparable 2-year OS rates of 59.4% and 60.8%, respectively (p = 0.9). In pooled multivariable regression, frontline TAG did not independently correlate with OS (HR 0.89, 95% CI 0.37–2.15; p = 0.803), whereas baseline peripheral blood involvement remained an independent predictor of worse OS (HR 2.63, 95% CI 1.1–6.27; p = 0.03). The authors conclude that frontline TAG is supported as an induction and bridging strategy to allogeneic transplantation, noting that unmeasured selection may contribute to the higher transplantation rate after TAG.
Key Takeaways
- Frontline tagraxofusp achieved an overall response rate of 82.1% and a complete response rate of 60.7%, with 2-year overall survival and progression-free survival rates reaching 40.5% and 30.4%, respectively.
- Capillary leak syndrome occurred in 53.1% of patients receiving tagraxofusp (grade ≥ 3 in 47.1%), presenting with no unexpected safety signals.
- Consolidation with allogeneic stem cell transplantation following tagraxofusp was achieved in nearly half of patients and trended toward improved survival (HR 0.25, 95% CI 0.06–1.14; p = 0.073), whereas baseline peripheral blood involvement independently predicted reduced survival (HR 2.63, 95% CI 1.1–6.27; p = 0.03).
Read the original sourceJournal of Hematology & Oncology
